

Case Report

Copyright © All rights are reserved by Patricia Alejandra Garrido Ruiz

# Giant Meningioma of The Olfactory Groove in A Transsexual Patient Undergoing Treatment with Cyproterone Acetate and Estradiol for Gender Transition

Patricia Alejandra Garrido Ruiz<sup>1\*</sup>, Juan Carlos Roa<sup>1</sup>, Andoni García<sup>1</sup>, Daniel Pascual<sup>1</sup>, Laura Ruiz<sup>1</sup>, Javier Pérez<sup>1</sup>, JM Gonçalves<sup>1</sup>, Álvaro Otero<sup>1</sup>, Juan José Ailagás<sup>1</sup> and Marta Román Garrido<sup>2</sup>

<sup>1</sup>Neurosurgery Department, Hospital Universitario de Salamanca, Spain

<sup>2</sup>Primary Care Department, Hospital Universitario de Salamanca, Spain

**Corresponding author:** Patricia Alejandra Garrido Ruiz, Neurosurgery Department, Hospital Universitario de Salamanca, Pº de San Vicente, 182, 37007 Salamanca; Servicio de Neurocirugía: 4ª Planta, Bloque D, Spain.

**Received Date:** June 09, 2023

**Published Date:** July 20, 2023

## Abstract

Possible complications that may occur and how to solve them before surgery are essential. This case is of special interest for being a low-incidence pathology in a rare location. The case is of high interest because of the importance of resecting the lesion to prevent sequels and the complexity of its management and highlights the importance of considering the diagnosis of this event after hormone therapy.

**Keywords:** Meningioma; Hormone therapy; Olfactory groove; Cyproterone acetate

## Introduction


Presentation of a 7.5 cm giant olfactory groove meningioma case in a 52-year-old patient undergoing treatment with hormone therapy to transition to the female gender. The case is of great interest because the olfactory groove is a rare location, constituting 4.5% of all meningiomas [1-3]. And for having hormone therapy as a probable etiology and growth facilitator of the meningioma given a long time of exposure per cumulative dose for 10 years.

## Case Report

A 52-year-old patient who, after 10 years of hormone therapy with cyproterone acetate 50 mg every 12 hours and estradiol patches of 100 micrograms every 3 days due to gender dysphoria to make a female gender transition, presented with oppressive headache in the bilateral fronto-parietal region and alterations of the behavior of recent onset, associated with personal carelessness. No focalities. A brain CT revealed a 7.5x 6.4x 4.5 cm extra axial tumor in the anterior cranial fossa with a base of implantation on

the floor of the same. A left supraorbital lateral craniotomy [4,5], was performed with complete Simpson I resection, revealing in the pathology a grade I meningioma with a fibroblastic histological pattern. Persisting at present without neurological focalities [6,7].


The observation that meningioma cell lines proliferate after exposure to progesterone and estrogen provide molecular and physiologic evidence for a potential role of sex steroid hormones in the development and growth of meningioma. Clinical evidence suggesting that meningioma might be a hormone-sensitive tumor is based on observations of higher incidence in women than in men, an observed increased growth of meningioma during pregnancy and menses, increased incidence of meningioma in women with breast cancer, and a higher prevalence in women with lymphangioleiomyomatosis, a cystic lung disease that is commonly treated long term with progesterone and other hormonal agents [8]. (Figures 1-5)



**Figure 1:** Axial MRI.




**Figure 2:** Sagittal MRI.



**Figure 3:** Coronal MRI.



**Figure 4:** Postsurgical Axial CT.



**Figure 5:** Postsurgical Sagittal MRI.

## Conclusion

It is suggested that hormones may be part of the etiology of meningiomas since they may present a large number of estradiol receptors. Although hormonal therapies are not associated with meningioma in women, the risk in men has been observed with even short-term, high-dose therapy. The increased risk of both single and multiple meningiomas due to the use of high-dose cyproterone acetate has been described in the literature and by the Spanish Agency for Medicines and Health Products [9-11]. This risk increases with the accumulated dose and should be discontinued after diagnosis.

## Acknowledgement

None.

## Conflict of Interest

The authors declare no conflicts of interest.

## References

1. Youmans (2016) Neurological Surgery. 7<sup>th</sup> Edition. Saunders Company.
2. Rhoton AL (2019) Rhoton Cranial Anatomy and Surgical Approaches. Oxford University Press. Congress of Neurological Surgeons.
3. M Greenberg (2019) Handbook of Neurosurgery, Thieme. 9<sup>th</sup> Edition.
4. Aguiar PH, Tahara A, Almeida AN, Simm R, Silva AN, et al. (2009) Olfactory groove meningiomas: approaches and complications. *J Clin Neurosci* 16(9): 1168-1173.
5. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL (1985) Meningioma: analysis of recurrence and progression following neurosurgical resection. *J Neurosurg* 62(1): 18-24.
6. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. *J Neurol Neurosurg Psychiatry* 20(1): 22-39.
7. Dehdashti AR, Ganna A, Witterick I, Gentili F (2009) Expanded endoscopic endonasal approach for anterior cranial base and suprasellar lesions: indications and limitations. *Neurosurgery* 64(4): 677-687.
8. Moss J, DeCastro R, Patronas NJ, Taveira-DaSilva A (2001) Meningiomas in lymphangioleiomyomatosis. *JAMA* 286(15): 1879-1881.

9. Carroll RS, Zhang J, Black PM (1999) Expression of estrogen receptors alpha and beta in human meningiomas. *J Neurooncol* 42(2): 109-116.
10. Hsu DW, Efrid JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: Prognostic considerations. *J Neurosurg* 86(1):113-120.
11. Jhavar BS, Fuchs CS, Golditz GA, Stampfer MJ (2003) Sex steroid hormone exposures and risk for meningioma. *J Neurosurg* 99(5): 848-853.